FANG-JU LINShyu, Kou-GiKou-GiShyuHsieh, I-ChangI-ChangHsiehHuey-Herng Sheu, WayneWayneHuey-Herng SheuTu, Shih-TeShih-TeTuYeh, Shoou-JengShoou-JengYehChen, Chin-IChin-IChenLu, Kuo-ChengKuo-ChengLuWu, Chia-ChaoChia-ChaoWuShau, Wen-YiWen-YiShauInocencio, Timothy JTimothy JInocencioWen, Yao-ChunYao-ChunWenYeh, Hung-IHung-IYeh2020-10-122020-10-122020-050929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/516779The recommended target low-density lipoprotein cholesterol (LDL-C) level for coronary artery disease (CAD) patients has been lowered from 100 to 70 mg/dL in several clinical guidelines for secondary prevention. We aimed to assess whether initiating statin treatment in CAD patients with baseline LDL-C 70-100 mg/dL in Taiwan could be cost-effective.animationCoronary artery disease; Cost-effectiveness analysis; Low-density lipoprotein cholesterol; Secondary prevention; Statin[SDGs]SDG3atorvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; pitavastatin; rosuvastatin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; low density lipoprotein cholesterol; Article; cardiac patient; cerebrovascular accident; cohort analysis; coronary artery disease; cost effectiveness analysis; drug cost; drug use; gross national product; health care cost; health status; heart infarction; human; incidence; major clinical study; Markov chain; mortality rate; probability; quality adjusted life year; recurrent disease; secondary prevention; sensitivity analysis; Taiwan; coronary artery disease; cost benefit analysis; economics; epidemiology; secondary prevention; Cholesterol, LDL; Coronary Artery Disease; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quality-Adjusted Life Years; Secondary Prevention; Taiwanjournal article10.1016/j.jfma.2020.01.01032081563WOS:000544560600003